Engineered immune cells take on HIV-Linked cancer in new trial
Disease control
Recruiting now
This phase 1 trial is testing a CAR-T cell therapy called axicabtagene ciloleucel in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack can…
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Apr 29, 2026 06:26 UTC